ArticleDevelopment (Cambridge, England)2026
Regulation of endothelial cell chromatin availability and transcription factor activity during arterial-venous specification.
Article in Development (Cambridge, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Arterial-venous specification of endothelial cells during vascular development requires coordination between intracellular signaling, cell cycle state and transcription factor activity. However, the intrinsic regulatory mechanisms that govern these processes are poorly understood. To investigate this, we assessed endothelial chromatin accessibility during vascular development. Murine postnatal day (P) 6 and P15 retinal endothelial cells were analyzed by single cell assay for transposase accessible chromatin sequencing, revealing heterogeneous chromatin accessibility across an arterial-venous continuum and in distinct cell cycle states. Enhancer regulatory network analysis predicted transcription factors with differential cell cycle and arterial-venous activity, and many with dual activator and repressor functions, including SOX17. We then validated SOX17 function in human endothelial cells, identifying that it inhibits proliferation and promotes arterial gene expression. Our findings suggest that dual roles of key endothelial transcription factors are regulated by chromatin accessibility in a cell cycle- and subtype-specific manner to control arterial-venous specification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.